Mentor Capital, Inc. Public Market (MNTR) Proxy For Cancer Immunology Leader Quantum Immunologics

Mentor Capital, Inc. (MNTR) and Quantum Immunologics, Inc. bring together $145 Million in public financing authorization with leading edge breast cancer immunotherapy now in FDA trials.

Instead of enduring mastectomies, chemotherapy and radiation, patients receiving in MNTR / Quantum's patented Oncofetal Antigen (OFA) dendritic therapy process report only flu-like symtoms that naturally follow any immune system activation.

OFA has been found on all 500 cancers tested and is not found on healthy tissue.